Notice of Results

RNS Number : 5887Y

IXICO plc

10 May 2019

 

10 May 2019

IXICO plc

("IXICO" or the "Company")

Notice of Results

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, will announce its interim results for the six months ended 31 March 2019 on Wednesday, 22 May 2019.

Giulio Cerroni, CEO and Grant Nash, CFO, will host a breakfast briefing and call for analysts at 09:00 BST on the day of the results at Cenkos Securities, 6-8 Tokenhouse Yard, London EC2R 7AS.

For further information please contact:

IXICO plc	[phone]
Giulio Cerroni, Chief Executive Officer
Cenkos Securities PLC (Nominated adviser and sole broker)	[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Optimum Strategic Communications	[phone]
Mary Clark / Anne Marieke Ezendam / Supriya Mathur
[e-mail]

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

 

END

 

 

NORDBGDUGBGBGCC